File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cardiovascular benefts of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study

TitleCardiovascular benefts of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study
Authors
Wong, CKHLau, TKKTANG, HMLee, CHPLee, CYYWoo, YCAU, CHTan, KCBLui, TWD
Issue Date2022
PublisherBMC. The Journal's web site is located at http://www.cardiab.com/
Citation
Cardiovascular Diabetology, 2022, v. 21, p. 92 How to Cite?
DOI: http://dx.doi.org/10.1186/s12933-022-01520-w
AbstractSodium-glucose cotransporter-2 inhibitors (SGLT2i) have proven cardiovascular benefits in patients with type 2 diabetes (T2D). This self-controlled case series study aims to evaluate whether metformin use and SGLT2i-associated erythrocytosis influence its cardiovascular benefits.
Persistent Identifierhttp://hdl.handle.net/10722/313445
ISI Accession Number ID
WOS:000805770700002

 

DC FieldValueLanguage
dc.contributor.authorWong, CKH-
dc.contributor.authorLau, TKK-
dc.contributor.authorTANG, HM-
dc.contributor.authorLee, CHP-
dc.contributor.authorLee, CYY-
dc.contributor.authorWoo, YC-
dc.contributor.authorAU, CH-
dc.contributor.authorTan, KCB-
dc.contributor.authorLui, TWD-
dc.date.accessioned2022-06-17T06:46:31Z-
dc.date.available2022-06-17T06:46:31Z-
dc.date.issued2022-
dc.identifier.citationCardiovascular Diabetology, 2022, v. 21, p. 92-
dc.identifier.urihttp://hdl.handle.net/10722/313445-
dc.description.abstractSodium-glucose cotransporter-2 inhibitors (SGLT2i) have proven cardiovascular benefits in patients with type 2 diabetes (T2D). This self-controlled case series study aims to evaluate whether metformin use and SGLT2i-associated erythrocytosis influence its cardiovascular benefits.-
dc.languageeng-
dc.publisherBMC. The Journal's web site is located at http://www.cardiab.com/-
dc.relation.ispartofCardiovascular Diabetology-
dc.titleCardiovascular benefts of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study-
dc.typeArticle-
dc.identifier.emailWong, CKH: carlosho@hku.hk-
dc.identifier.emailLau, TKK: kristytk@hku.hk-
dc.identifier.emailLee, CHP: pchlee@hku.hk-
dc.identifier.emailWoo, YC: wooyucho@hku.hk-
dc.identifier.emailTan, KCB: kcbtan@hkucc.hku.hk-
dc.identifier.emailLui, TWD: dtwlui@hku.hk-
dc.identifier.authorityWong, CKH=rp01931-
dc.identifier.authorityLee, CHP=rp02043-
dc.identifier.authorityTan, KCB=rp00402-
dc.identifier.authorityLui, TWD=rp02803-
dc.identifier.doi10.1186/s12933-022-01520-w-
dc.identifier.hkuros333448-
dc.identifier.volume21-
dc.identifier.spage92-
dc.identifier.epage92-
dc.identifier.isiWOS:000805770700002-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats